Undifferentiated Pleomorphic Sarcoma Clinical Trial
Official title:
Phase Ib Trial Evaluating the Combination of CDK4 Inhibitor With Immunotherapy in Patients With Undifferentiated Pleomorphic Sarcoma (UPS)
This is a single-arm open-label window of opportunity clinical study assessing the impact of pre- treatment with palbociclib
This is a single-arm open-label window of opportunity clinical study assessing the impact of pre- treatment with palbociclib. Patients with be given palbociclib for 2 weeks following a pre-treatment ultrasound guided biopsy used to establish an immunological baseline of the tumor microenvironment. After the conclusion of palbociclib therapy, a post-treatment biopsy will be performed to assess the impact of palbociclib on the tumor microenvironment; pembrolizumab will be started the same day as the second biopsy. After 2 doses of pembrolizumab, a third (optional) biopsy could be performed. At 8 weeks of therapy disease response will be assessed as per standard of care. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05515068 -
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
|
||
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Completed |
NCT02565758 -
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03307616 -
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
|
Phase 2 | |
| Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
| Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03899805 -
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
|
Phase 2 | |
| Active, not recruiting |
NCT03752398 -
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
|
Phase 1 | |
| Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT03989596 -
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
|
Phase 2 | |
| Not yet recruiting |
NCT03946943 -
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04008238 -
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
|
N/A | |
| Recruiting |
NCT04123535 -
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
|
N/A | |
| Active, not recruiting |
NCT04242238 -
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
|
Phase 1 | |
| Completed |
NCT02584309 -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT03425279 -
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03651375 -
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
|
Phase 2 | |
| Recruiting |
NCT04480502 -
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
|
Phase 2 |